9-ING-41 in Pediatric Patients with Refractory Malignancies. - Join Clinical Trial NCTNCT04239092
How to Join This Clinical Trial - NCTNCT04239092
Learn how to participate in this PHASE1 trial studying an investigational therapy for Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma. Current status: TERMINATED.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE1 - Early safety study
- Enrollment Status
- TERMINATED
- Study Identifier
- NCTNCT04239092 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 9 locations. Find a study site near you:
Clinical Research Site
San Francisco, California 94158-2549 - United States
Status: RECRUITING
Clinical Research Site
Aurora, Colorado 80045 - United States
Status: RECRUITING
Clinical Research Site
Chicago, Illinois 60637 - United States
Status: RECRUITING
Clinical Research Site
Ann Arbor, Michigan 48109 - United States
Status: RECRUITING
Clinical Research Site
Charlotte, North Carolina 28204 - United States
Status: RECRUITING
Clinical Research Site
Durham, North Carolina 27708 - United States
Status: RECRUITING
Clinical Research Site
Providence, Rhode Island 02912 - United States
Status: COMPLETED
Clinical Research Site
Houston, Texas 77030 - United States
Status: RECRUITING
Clinical Research Site
Seattle, Washington 98101 - United States
Status: RECRUITING
How to Enroll in This Study
To learn more about participating in this PHASE1 clinical trial for Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai as Your Clinical Trial Matching Service
Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:
- Find clinical trials that match your condition
- Get matched to the right study location near you
- Connect directly with study coordinators
- Understand if you qualify with simplified eligibility screening
- Navigate the enrollment process with personalized support
- Access new treatments through clinical research participation